GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Ending Cash Position

Beijing Bohui Innovation Biotechnology Group Co (SZSE:300318) Ending Cash Position : ¥259.8 Mil (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Bohui Innovation Biotechnology Group Co Ending Cash Position?

Beijing Bohui Innovation Biotechnology Group Co's Ending Cash Position for the quarter that ended in Mar. 2025 was ¥259.8 Mil.

Beijing Bohui Innovation Biotechnology Group Co's quarterly Ending Cash Position declined from Sep. 2024 (¥97.3 Mil) to Dec. 2024 (¥55.9 Mil) but then increased from Dec. 2024 (¥55.9 Mil) to Mar. 2025 (¥259.8 Mil).

Beijing Bohui Innovation Biotechnology Group Co's annual Ending Cash Position declined from Dec. 2022 (¥107.8 Mil) to Dec. 2023 (¥83.8 Mil) and declined from Dec. 2023 (¥83.8 Mil) to Dec. 2024 (¥55.9 Mil).

Beijing Bohui Innovation Biotechnology Group Co Ending Cash Position Historical Data

The historical data trend for Beijing Bohui Innovation Biotechnology Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Bohui Innovation Biotechnology Group Co Ending Cash Position Chart

Beijing Bohui Innovation Biotechnology Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.19 34.47 107.80 83.79 55.94

Beijing Bohui Innovation Biotechnology Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.47 65.14 97.27 55.94 259.77

Beijing Bohui Innovation Biotechnology Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Beijing Bohui Innovation Biotechnology Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=83.789+-27.85
=55.9

Beijing Bohui Innovation Biotechnology Group Co's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=55.94+203.832
=259.8

Beijing Bohui Innovation Biotechnology Group Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Beijing Bohui Innovation Biotechnology Group Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Bohui Innovation Biotechnology Group Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Bohui Innovation Biotechnology Group Co Ltd (SZSE:300318) » Definitions » Ending Cash Position
Comparable Companies
SHSE:688075 SHSE:603590 SZSE:300497 SZSE:300871 BJSE:839273 SHSE:688767 SHSE:688293 SHSE:688046 SHSE:688488 SZSE:301333 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
Block G Jingxinyuan, NO.25 Jia Beiwucun Road, Haidian, Beijing, CHN, 100097
Website
http://www.bohui-tech.com
Beijing Bohui Innovation Biotechnology Group Co Ltd is a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. The company focuses on the research and development, production, sales, and after-sales services of in vitro diagnostic products. The Company's business involved two segments: inspection and testing and biological products. The Biological segment generated the majority of its revenue which engaged in the research and development, production, and sales of blood products, the product range covers human blood albumin, human immunoglobulin, and human coagulation factor three categories of multiple varieties, basically covering the important varieties of blood products.
Executives
Niu Shu Hui Executives
Di Xiao Feng Director
Yang Qi Director
Lu Xin Qun Directors, executives
Zhang Lei Director
Wan Zhang Geng Executives
Song Rui Directors, executives

Beijing Bohui Innovation Biotechnology Group Co Headlines

No Headlines